Nasdaq · CIK 0001494891
SRTS Sensus Healthcare, Inc.
Insider trading from SEC Form 4. Last filing Feb 26, 2026. Close $2.95 on Oct 9, 2026, +10% from the 52-week low and -44% from the high.
Sensus Healthcare, Inc. (SRTS) has 15 SEC Form 4 filings on file from 6 insiders, the latest filed on Feb 26, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
9 open-market trades have been scored at SRTS. The newest: Eric Sachetta (director) bought $7,620 of stock on Feb 24, 2026, filed Feb 26, 2026, scored 23 (weak). The largest of the 9 shown: Joseph C Sardano (CHIEF EXECUTIVE OFFICER) bought $101k on Nov 18, 2025, scored 50 (moderate). 3 insiders bought within 14 days of each other around Nov 21, 2025.
SRTS closed at $2.95 on Oct 9, 2026, 10% above its 52-week low and 44% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Sensus Healthcare, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Eric Sachetta director buy | $7,620 2,000 shares | +1% | +24% from low-32% from high | |
| 43Moderate | Eric Sachetta director buy | $28k 7,000 shares | +5% | - | |
| 30Weak | Eric Sachetta director buy | $11k 2,500 shares | +2% | - | |
| 50Moderate | Joseph C Sardano CHIEF EXECUTIVE OFFICER buy | $101k 25,000 shares | +2% | - | |
| 35Weak | Michael Sardano PRESIDENT AND GENERAL COUNSEL buy | $3,800 1,000 shares | +1% | - | |
| 40Moderate | Michael Sardano PRESIDENT AND GENERAL COUNSEL buy | $8,546 2,000 shares | +2% | - | |
| 40Moderate | Michael Sardano PRESIDENT AND GENERAL COUNSEL buy | $8,523 2,000 shares | +2% | - | |
| 35Weak | Michael Sardano PRESIDENT AND GENERAL COUNSEL buy | $4,260 1,000 shares | +1% | - | |
| 15Weak | Michael Sardano PRESIDENT AND GENERAL COUNSEL buy | $3,370 1,000 shares | +1% | - |
Transactions
Every row filed, 18 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Eric Sachetta director | POpen-market purchase Common Stock | +2,000 | $3.81 | $7,620 | 142,113 | Feb 26, 2026 |
| Dec 12, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 158,839 | Dec 16, 2025 |
| Nov 21, 2025 | Eric Sachetta director | POpen-market purchase Common Stock | +7,000 | $3.93 | $28k | 140,113 | Nov 21, 2025 |
| Nov 13, 2025 | Eric Sachetta director | POpen-market purchase Common Stock | +2,500 | $4.50 | $11k | 133,113 | Nov 20, 2025 |
| Nov 18, 2025 | Joseph C Sardano CHIEF EXECUTIVE OFFICER | POpen-market purchase Common Stock | +25,000 | $4.03 | $101k | 1,200,293 | Nov 19, 2025 |
| Nov 18, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | POpen-market purchase Common Stock | +1,000 | $3.80 | $3,800 | 118,839 | Nov 19, 2025 |
| Nov 11, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | POpen-market purchase Common Stock | +1,000 | $4.26 | $4,260 | 117,839 | Nov 18, 2025 |
| Nov 11, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | POpen-market purchase Common Stockindirect: spouse | +766 | $4.27 | $3,271 | 766 | Nov 18, 2025 |
| Nov 11, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | POpen-market purchase Common Stockindirect: spouse | +234 | $4.34 | $1,016 | 1,000 | Nov 18, 2025 |
| Nov 11, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | POpen-market purchase Common Stock | +1,000 | $4.26 | $4,260 | 117,839 | Nov 13, 2025 |
| Nov 11, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | POpen-market purchase Common Stockindirect: spouse | +766 | $4.27 | $3,271 | 118,605 | Nov 13, 2025 |
| Nov 11, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | POpen-market purchase Common Stockindirect: spouse | +234 | $4.24 | $992 | 118,839 | Nov 13, 2025 |
| Nov 11, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | POpen-market purchase Common Stock | +1,000 | $4.26 | $4,260 | 117,839 | Nov 12, 2025 |
| Aug 13, 2025 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | POpen-market purchase Common Stock | +1,000 | $3.37 | $3,370 | 116,839 | Aug 14, 2025 |
| Dec 17, 2024 | Megan Cornish director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 32,000 | Dec 19, 2024 |
| Dec 17, 2024 | William H McCall director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 30,000 | Dec 19, 2024 |
| Dec 17, 2024 | Anthony Benedict Petrelli director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 66,466 | Dec 19, 2024 |
| Dec 17, 2024 | Michael Sardano PRESIDENT AND GENERAL COUNSEL | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 114,839 | Dec 19, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Megan Cornishdirector
- William H McCalldirector
- Anthony Benedict Petrellidirector
- Eric Sachettadirector
- Joseph C SardanoCHIEF EXECUTIVE OFFICER
- Michael SardanoPRESIDENT AND GENERAL COUNSEL
Questions about SRTS
Answered from the filings on this page, as of the latest one.
Are insiders buying SRTS?
No. In the last 90 days no insider at Sensus Healthcare, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SRTS on the open market?
Eric Sachetta (director) bought $7,620 of SRTS on Feb 24, 2026 and filed the Form 4 on Feb 26, 2026. InsiderTell scored 23 (weak).
How many insiders file Form 4 at Sensus Healthcare, Inc.?
6 people have filed a Form 4 at Sensus Healthcare, Inc., among them Megan Cornish (director), William H McCall (director), Anthony Benedict Petrelli (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.